The level of serum visfatin (PBEF) is associated with total number of B cells in patients with rheumatoid arthritis and decreases following B cell depletion therapy

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F11%3A9584" target="_blank" >RIV/00216208:11110/11:9584 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00023728:_____/11:#0001050 RIV/00064165:_____/11:9584

Výsledek na webu

<a href="http://dx.doi.org/10.1016/j.cyto.2011.04.004" target="_blank" >http://dx.doi.org/10.1016/j.cyto.2011.04.004</a>

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

The level of serum visfatin (PBEF) is associated with total number of B cells in patients with rheumatoid arthritis and decreases following B cell depletion therapy

Popis výsledku v původním jazyce

Objective: Visfatin, also known as pre-B cell colony-enhancing factor, was recently characterized as a potent pro-inflammatory mediator in rheumatoid arthritis (RA). The aim of this study was to determine the effect of B cell depletion with rituximab onserum visfatin levels in patients with active RA. Methods: We evaluated 31 patients with RA starting rituximab therapy at baseline and after 16 and 24 weeks using disease activity score (DAS28). The control group consisted of 33 gender and age-matched healthy individuals. CD19(+) B cells were assessed by flow cytometry and serum levels of visfatin and B cell-activating factor of the TNF family (BAFF) were measured by ELISA at baseline and week 16. Results: Total number of B cells correlated positively with serum visfatin levels (rs = 0.417, P = 0.025) and negatively with serum BAFF levels (rs = -0.486, P = 0.008) at baseline. Serum visfatin levels were significantly higher in patients with RA compared with healthy controls (P = 0.026),

Název v anglickém jazyce

The level of serum visfatin (PBEF) is associated with total number of B cells in patients with rheumatoid arthritis and decreases following B cell depletion therapy

Popis výsledku anglicky

Objective: Visfatin, also known as pre-B cell colony-enhancing factor, was recently characterized as a potent pro-inflammatory mediator in rheumatoid arthritis (RA). The aim of this study was to determine the effect of B cell depletion with rituximab onserum visfatin levels in patients with active RA. Methods: We evaluated 31 patients with RA starting rituximab therapy at baseline and after 16 and 24 weeks using disease activity score (DAS28). The control group consisted of 33 gender and age-matched healthy individuals. CD19(+) B cells were assessed by flow cytometry and serum levels of visfatin and B cell-activating factor of the TNF family (BAFF) were measured by ELISA at baseline and week 16. Results: Total number of B cells correlated positively with serum visfatin levels (rs = 0.417, P = 0.025) and negatively with serum BAFF levels (rs = -0.486, P = 0.008) at baseline. Serum visfatin levels were significantly higher in patients with RA compared with healthy controls (P = 0.026),

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

EC - Imunologie

OECD FORD obor

—

Projekt

<a href="/cs/project/NS10614" target="_blank" >NS10614: Prognostický význam adipokinů u revmatoidní artritidy</a><br>

Návaznosti

S - Specificky vyzkum na vysokych skolach

Rok uplatnění

2011

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Cytokine

ISSN

1043-4666

e-ISSN

—

Svazek periodika

55

Číslo periodika v rámci svazku

1

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

6

Strana od-do

116-121

Kód UT WoS článku

000291916300018

EID výsledku v databázi Scopus

—